MyFiziq's agreement with Bearn LLC ratified

|

Published 06-MAY-2020 11:48 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

MyFiziq Limited (ASX:MYQ) has signed definitive agreements with Bearn LLC in North America in relation to its transformative Bearn Application app, Bearn LLC.

Bearn and MyFiziq have now collaborated and integrated MyFiziq’s body tracking application into the Bearn application, and Bearn’s users will have the ability to ‘earn while they Bearn’ on the platform.

The users will be able to use the cash they have earned to use the tracking technology as part of their goal setting and the journey they undertake on the Bearn application.

MyFiziq will be an integral part of Bearn’s offering as the primary checkpoint of dimensional and body composition change.

Users earn cash for improving the health

Bearn presents a unique multi-sided vendor backed platform that allows for the gamification and engagement of health with users.

Users earn actual cash for improving their health, fitness and wellness, demonstrating a 75% retention of its users.

Bearn is targeting the full launch of the application in May 2020.

The group’s users will also earn access to the MyFiziq tracking technology under the Bearn reward program where they will receive an ability to check their changes and track their goals that are being achieved each week through the workouts and nutrition programs using the dollars they have earned.

MyFiziq will be paid US$2.00 per scan from Bearn.

US launch is imminent

Commenting on progress made in recent months and discussing the upcoming US launch, MyFiziq chief executive Vlado Bosanac said, “The combined application with Bearn is nearing completion with the MyFiziq development team and the Bearn development team, having spent the last 8 weeks working together completing full integration.

‘’In addition, Bearn has made the application available in its beta download for testing.

‘’The feedback has been great, and we made a number of user experience changes based on this feedback information on the beta version of the app.

‘’The launch of the application into the US is one step closer with the completion of the legal agreements. Bearn has done a great job working with our team to get this build completed.’’



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X